Hospital CUF Descobertas
Lisbon, Portugal
5 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled536 locationsNCT06492616
Recruiting
Phase 2Phase 3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Biogen450 enrolled314 locationsNCT05531565
Recruiting
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
All Tumor Types
European Organisation for Research and Treatment of Cancer - EORTC4,975 enrolled134 locationsNCT02834884
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Primary Sjogrens Disease
argenx580 enrolled304 locationsNCT06684847
Recruiting
Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Episodic Migraine
H. Lundbeck A/S315 enrolled65 locationsNCT05897320
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285